Primary pulmonary alveolar soft part sarcoma with ASPSCR1–TFE3 gene fusion: Case report and literature review

Xijian Hu,Jing Chai,Bin Zhang,Chengguang Hu
DOI: https://doi.org/10.1097/md.0000000000040249
IF: 1.6
2024-11-06
Medicine
Abstract:Alveolar soft part sarcoma (ASPS) is a rare tumor of uncertain histogenesis, accounting for only 0.5% to 1% of all soft tissue tumors. [ 1 ] The overall 2-year survival rate is 82%, and 5-year survival rate is 56%. [ 2 ] ASPS is characterized by der(17)t(X;17)(p11;q25) resulting in ASPSCR1–TFE3 fusion. [ 3 ] Demonstration of this particular gene rearrangement is the most desirable diagnostic criterion of ASPS. Conventional chemotherapy and radiation therapy are not beneficial in most previous studies. [ 4 ] Surgical excision is the main treatment method for ASPS, and has been reported to improve the prognosis of both patients with localized disease and distant metastases. [ 2 ] Primary pulmonary ASPS is extremely rare. Literature to date reported only 6 instances of primary pulmonary ASPS. [ 5–10 ] Due to financial and technical considerations, only 2 of the 6 cases confirmed the presence of ASPSCR1–TFE3 fusion. [ 6 , 7 ] This study reported a 27-year-old male case of primary pulmonary ASPS with confirmed ASPSCR1–TFE3 fusion and reviewed the currently published literature.
medicine, general & internal
What problem does this paper attempt to address?